Drug Trial Radar · NCT00044811
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
Last checked: Nov 19, 2026Latest source record: Aug 21, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Planned (sponsor's estimate)
Start
Mar 2002
Primary completion
Oct 2003
Study completion Oct 2003
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 17, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
Conditions
- Asthma
Interventions
FexofenadineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Forced expiratory volume FEV1.
Locations
7 sites in 7 countries. Site status is shown where the registry gives one.
Aventis Pharmaceuticals Inc.
Bridgewater, New Jersey
Sanofi-Aventis Admnistrative Office
Costa Rica, Costa Rica
Sanofi-Aventis Administrative Office
Guatemala City, Guatemala
Sanofi-Aventis Administrative Office
Budapest, Hungary
Sanofi-Aventis Administrative Office
México, Mexico
Sanofi-Aventis Administrative Office
Warsaw, Poland
Sanofi-Aventis Administrative Office
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.